Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer

SIMPLE SUMMARY: In this study, we measured the plasmatic concentration of Kinase inhibitors (KI) among a population with non-small cell lung cancer (NSCLC) harboring driver genetic alterations. They received erlotinib, gefitinib, osimertinib, crizotinib, or dabrafenib (with or without trametinib) fo...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancers (Basel)
Autori principali: Geraud, Arthur, Mezquita, Laura, Auclin, Edouard, Combarel, David, Delahousse, Julia, Gougis, Paul, Massard, Christophe, Jovelet, Cécile, Caramella, Caroline, Adam, Julien, Naltet, Charles, Lavaud, Pernelle, Gazzah, Anas, Lacroix, Ludovic, Rouleau, Etienne, Vasseur, Damien, Mir, Olivier, Planchard, David, Paci, Angelo, Besse, Benjamin
Natura: Artigo
Lingua:Inglês
Pubblicazione: MDPI 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7764991/
https://ncbi.nlm.nih.gov/pubmed/33327482
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12123758
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi